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ABSTRACT
The concept that solid tumors are maintained by a productive interplay between 
neoplastic and non-neoplastic elements has gained traction with the demonstration that 
stromal fibroblasts and immune system cells dictate cancer development and progression. 
While less studied, brain tumor (glioma) biology is likewise influenced by non-neoplastic 
immune system cells (macrophages and microglia) which interact with neoplastic glioma 
cells to create a unique physiological state (glioma ecosystem) distinct from that found 
in the normal tissue. To explore this neoplastic ground state, we leveraged several 
preclinical mouse models of neurofibromatosis type 1 (NF1) optic glioma, a low-grade 
astrocytoma whose formation and maintenance requires productive interactions between 
non-neoplastic and neoplastic cells, and employed whole tumor RNA-sequencing and 
mathematical deconvolution strategies to characterize this low-grade glioma ecosystem 
as an aggregate of cellular and acellular elements. Using this approach, we demonstrate 
that optic gliomas generated by altering the germline Nf1 gene mutation, the glioma 
cell of origin, or the presence of co-existing genetic alterations represent molecularly-
distinct tumors. However, these optic glioma tumors share a 25-gene core signature, 
not found in normal optic nerve, that is normalized by microglia inhibition (minocycline), 
but not conventional (carboplatin) or molecularly-targeted (rapamycin) chemotherapy. 
Lastly, we identify a genetic signature conferred by Pten reduction and corrected by 
PI3K inhibition. This signature predicts progression-free survival in patients with either 
low-grade or high-grade glioma. Collectively, these findings support the concept that 
gliomas are composite ecological systems whose biology and response to therapy may 
be best defined by examining the tumor as a whole.
INTRODUCTION
Histological examination of most solid tumors 
reveals that these cancers are composed of numerous 
distinct cell types, which are embedded in a rich 
extracellular matrix containing growth factors and 
cytokines. Among the cell types in these tumors are 
differentiated and stem-like neoplastic cells, as well as 
non-neoplastic cells, such as monocytes, fibroblasts, 
and endothelial cells [1]. With the recognition that the 
biological behaviors of many solid cancers are dictated 
by the productive interactions between these diverse 
cellular and acellular elements, the concept of a cancer 
ecosystem has been advanced [2–4]. In support of this 
concept, non-neoplastic stromal cells, such as fibroblasts 
and immune system cells, have been shown to drive solid 
tumor development and progression [5, 6]. Within the 
central nervous system, brain tumor (glioma) growth in 
experimental mouse models is similarly controlled by 
specific monocyte populations, including microglia and 
macrophages, that are recruited by the tumor cells through 
the elaboration of chemokines, like colony stimulating 
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factor 1 (CSF-1) [7]. Additionally, productive interactions 
between monocytes and glioma cells create a feed-forward 
paracrine circuit that perpetuates high-grade glioma 
growth [8–10]. These studies in high-grade malignancies 
have suggested alternative approaches to cancer treatment, 
in which targeted therapies against stromal cell types or 
signals might emerge as a potential adjuvant approaches 
[11–15].
One of the clinical situations where stromal therapies 
might be particularly useful is in the treatment of pediatric 
low-grade tumors. Unlike adult high-grade malignancies, 
these tumors are slow growing (with proliferative indices 
often less than 1%) and arise in children whose brains are 
still developing. Therapies that target unique elements 
of the tumor ecosystem, not shared by the developing 
brain, would be highly desirable. This issue is well 
illustrated by the Neurofibromatosis type 1 (NF1) cancer 
predisposition syndrome, in which affected children are 
prone to the formation of low-grade nervous system 
tumors (peripheral nerve sheath tumors and optic pathway 
gliomas). Examination of these tumors reveals prominent 
immune system infiltration and interdependencies 
between neoplastic and non-neoplastic cell types [16–22]. 
Specifically, the formation and continued growth 
(maintenance) of low-grade optic gliomas in mice 
require a supportive tumor microenvironment containing 
microglia, which are attracted to the developing cancer 
by chemokines [20], and elaborate specific growth 
factors that promote neoplastic cell growth [19]. These 
cellular interactions could be hypothesized to create a 
new homeostatic state, not present in the non-neoplastic 
optic nerve, and thus establish new circuitries and 
interdependencies for chemotherapeutic targeting.
In the current study, we employed whole-tumor 
RNA-sequencing and mathematical deconvolution 
strategies using preclinical mouse models of Nf1 optic 
glioma to characterize the tumor ecosystem as an 
aggregate gene expression pattern distinct from the healthy 
optic nerve. Leveraging numerous different murine optic 
glioma genetically-engineered mouse (GEM) models, we 
found that histologically-similar tumors are molecularly 
distinct. However, despite their uniqueness, all Nf1 murine 
optic gliomas examined share a 25-gene expression 
signature that distinguishes tumor tissue from normal optic 
nerve. This core genetic signature was minimally affected 
by conventional (carboplatin) or biologically-targeted 
(rapamycin) therapy, but was normalized following 
minocycline treatment, which inhibits tumor-associated 
microglia function. Lastly, we discovered a PTEN/PI3K-
driven molecular signature that correlates with the overall 
survival of patients with either low-grade or high-grade 
glioma. Taken together, our study suggests that shared and 
unique whole-tumor gene expression patterns may serve 
as biomarkers of tumor response to therapy and patient 
survival. 
RESULTS AND DISCUSSION
Whole tumor RNA-sequencing of a diverse 
collection of Nf1 optic glioma tumors reveals 
molecularly-distinct neoplasms
In an effort to accurately represent the heterogeneity 
inherent in human NF1-associated optic pathway glioma 
(NF1-OPG), we have previously engineered mice that 
differ with respect to the germline Nf1 gene mutation 
(null allele (FMC) [23] versus NF1 patient germline 
NF1 gene mutation; R681* (F18C) [24]), the cell of 
origin (GFAP+ neuroglial progenitors (FMC) [23] versus 
Olig2+ progenitor cells (FMOC) (Solga A, manuscript 
in preparation)), and the presence of a co-existing 
heterozygous Pten deletion in the tumor cells (FMPC) 
[25, 26]. Using these four optic glioma strains, we 
performed whole tumor RNA-Seq on 27 specimens along 
with four normal age- and sex-matched optic nerves. Gene 
expression heatmap representation of all 31 samples across 
4,624 genes revealed differentially-expressed gene sets in 
at least one pairwise comparison relative to normal optic 
nerve, as well as between Nf1 GEM optic glioma models 
(Figure 1A). While some sample-to-sample heterogeneity 
was found between whole tumor specimens from the same 
GEM model, significantly larger differences among the 
four models were demonstrated by the average profiles 
(Figure 1B). Because these expression profiles were from 
homogenized whole tumor tissue, the observed molecular 
differences between models likely reflect contributions 
from multiple distinct cell types. However, despite clear 
differences in tumor latency, proliferative rates, and tumor 
volumes, immunohistochemical analyses of these tumors 
revealed only slight differences in the percentages of 
microglia (Iba1+ cells), astroglial (GFAP+ or S100β+ cells), 
or Olig2+ progenitor cells [23–25].
To better understand the murine Nf1 optic glioma 
ecosystem as a whole, we next sought to estimate the 
cell type-specific contributions to the observed gene 
expression differences. In previous studies, we and others 
have used computational approaches to deconvolve the 
data into potential cell type profiles. Whole transcriptome 
deconvolution requires two basic inputs - genome-
wide transcript abundances and a measure of cellular 
composition - both of which can be derived from RNA-Seq 
data. As demonstrated in our previous study, in which we 
applied deconvolution to human high-grade gliomas, we 
can use the abundance of a cell type-specific marker or set 
of markers for each cell type in any given tissue to estimate 
the fractional composition of each cell type [27, 28]. 
Hence, we are able to use the RNA expression levels of 
cell type-specific marker genes in the composite profiles 
of each specimen to solve for an estimated abundance of 
each gene in each cell type by least-squares regression. 
While this approach assumes that cell type-specific RNA 
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abundances are invariant across specimens, the fitting 
procedure allows us to restrict our analysis to genes with 
expression patterns that are fit well by this model. 
For these analyses, we specifically focused 
on glial cell populations (microglia and macroglia 
[oligodendrocytes, astrocytes, oligodendrocyte 
precursors]; Figure 1C–1F). As such, the glial cell type-
specific contributions for genes that are differentially 
expressed (padj<0.01, |log2(fold-change)| > 1) between 
each Nf1 GEM optic glioma model and normal optic 
nerve can be represented, as estimated by computational 
deconvolution. Using this approach, several important 
observations were made: First, all of the Nf1 GEM optic 
glioma models showed significant depletion of genes 
specific to mature oligodendrocytes compared to normal 
optic nerve (FF). Second, while all four models exhibited 
enrichment of oligodendrocyte progenitor cell (OPC) 
gene expression, this finding was most pronounced in 
the FMOC and FMC optic glioma models relative to the 
F18C and FMPC optic glioma models. Third, the largest 
distinction between the FMPC optic glioma model and 
the normal optic nerve was enrichment of astrocyte gene 
expression. This result suggests that Pten reduction, which 
is the only genetically-engineered difference between the 
FMC and FMPC optic glioma models, may alter the glial 
lineage character of the tumor. However, these changes in 
gene expression did not correlate with changes in Olig2+, 
NG2+ or GFAP+ cell numbers between Nf1 GEM optic 
glioma strains ([24, 25]; Supplementary Figure 1). The 
apparent disconnect between glial cell-estimated gene 
expression and actual glial cell numbers suggests that these 
differentially-expressed gene signatures reflect global 
changes in the tumor ecosystem, rather than alterations 
in overall tumor cellular composition. Moreover, analysis 
of previously-acquired RNA-sequencing data from FMC 
tumor-associated microglia relative to those from Nf1+/- 
mice [19] demonstrated that the differentially-expressed 
genes assigned to microglia by deconvolution were not 
similarly altered in the actual microglia from these tumors 
(data not shown). Collectively, these results support the 
notion that the gene expression patterns in the tumor do 
not reflect the individual contributions of each cell type, 
but rather the composite interactions of all cell types.
All Nf1 optic glioma GEM models share a core 
gene expression signature that is minocycline-
sensitive
While Figure 1 highlights the molecular differences 
among the four different Nf1 optic glioma models, all of 
Figure 1: (A) Heatmap of RNA-Seq expression z-scores computed for all genes that are differentially expressed (padj < 0.01, |log2(fold-
change)| > 1) between all pairwise comparisons of the optic glioma models and the healthy optic nerve (FF) controls.  Each column in the 
heatmap is an individual sample. (B) Same as (A), but averaged over all samples for each genotype. (C) Computational deconvolution of 
cell type-specific gene expression for genes that are differentially expressed between FMOC tumors and FF controls.  In the top panel, each 
row in the heatmap corresponds to a specific differentially-expressed gene and each column corresponds to a cell type. The lower panel 
shows the aggregate expression in each cell type for all genes that are high in FMOC or FF tumors. The analysis shows that the FMOC 
tumors are highly enriched in OPC-like gene expression. (D) Same as (C), but for differentially-expressed genes from the comparison of 
FMC tumors to FF controls. Similar to FMOC, the FMC tumors are also dominated by an OPC-like gene expression pattern. (E) Same as 
(C), but for differentially-expressed genes from the comparison of F18C tumors to FF controls. The F18C tumors have both higher OPC-
like and astrocytic gene expression relative to FF controls. (F) Same as (C), but for differentially-expressed genes from the comparison 
of FMPC tumors to FF controls, demonstrating a more pronounced astrocytic gene expression in FMPC gliomas. OPC, oligodendrocyte 
progenitor cell; Astro, astocyte; Oligo, oligodendrocyte.
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these tumors shared a core gene expression signature. 
In this regard, we identified a 25-gene signature that is 
universally differentially expressed (increased) relative to 
normal optic nerves across the 27 optic glioma specimens 
(Table 1; Figure 2A). Interestingly, this signature was 
most pronounced in the FMOC and FMC tumors and 
relatively diminished in the FMPC tumors.  Accordingly, 
our deconvolution model suggests that these genes are 
predominantly associated with OPC-like cells. While 
there are more GFAP+ cells in all Nf1 optic glioma models 
relative to the non-neoplastic optic nerve, there are only 
small differences in the relative proportions of Olig2+, 
GFAP+, or NG2+ glial cells between the various GEM 
models ([24, 25]; Supplementary Figure 1). In addition, 
GO-term analysis of the core genes did not reveal 
enrichment in specific categories (data not shown). As 
before, we favor the interpretation that this core signature 
represents a “neoplastic state” gene expression network 
established by the glioma ecosystem. Since this core gene 
expression signature distinguishes normal from tumor-
bearing optic nerve, we hypothesize that it might be used 
to identify brain tumor treatments that best normalize the 
glioma ecosystem.
To explore this idea further, we leveraged prior 
preclinical studies from our laboratory in which 
conventional and biologically-targeted chemotherapy 
agents were evaluated prior to clinical translation. While 
our previous preclinical experiments demonstrated that 
temozolomide (TMZ) is effective at inducing tumor 
death [29], we now employed carboplatin as a standard 
chemotherapy reference, as it is the first line therapy 
for children with NF1-OPG [30, 31]. Similar to that 
observed in FMC mice following TMZ treatment, 
carboplatin induced a significant reduction in both tumor 
volume and proliferation (%Ki67+ cells; Figure 2B). 
Additionally, we evaluated the effect of two biologically-
targeted therapies previously shown to inhibit mouse 
Nf1 optic glioma growth in vivo. We selected rapamycin 
(mechanistic target of rapamycin [mTOR] inhibitor; [29]) 
and minocycline (microglia inhibitor; [17]) to inhibit 
neoplastic and stromal cell function, respectively, in 
separate experiments. 
Table 1: Genes comprising the 25-core signature in all optic glioma models
Gene Name
Aldh1l1 aldehyde dehyrogenase 1 family member L1
Btbd3 BTB (POZ) domain-containing 3
Btbd17 BTB (POZ) domain-containing 17
Cd38 CD38
Cspg5 chondroitin sulfate proteoglycan 5 (Caleb)
Cxcl14 C-X-C motif chemokine ligand 14
Elmo2 engulfment and cell motility 2
Etv5 ets variant 5 (Erm)
Fabp5 fatty acid binding protein 5 (E-Fabp)
Fgfrl1 fibroblast growth factor receptor-like 1
Gja1 gap junction protein, alpha 1 (connexin-43)
Igdcc4 immunoglobulin superfamily DCC subclass member 4 (Nope)
Marcks myristoylated alanine-rich protein kinase C substrate
Ncan neurocan (Cspg3)
Ntsr2 neurotensin receptor 2
Pcdhgc3 protocadherin gamma subfamily C, 3
Pygm glycogen phosphorylase, muscle associated
S1pr1 sphingosine-1-phosphate receptor 1 (Edg1)
Sdc3 syndecan 3
Sfxn5 sideroflexin 5
Shc3 SHC adaptor protein 3 (N-Shc)
Slc6a11 solute carrier family 6 member 11 (Gat3)
Spry4 sprouty homolog 4
Tril TLR4 interactor with leucine-rich repeats
Wnt7b wingless-type MMPTV integration site family, member 7B
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Overall, we found that rapamycin treatment resulted 
in very few changes in the 25-core gene expression profile 
compared to carboplatin and minocycline. This result is 
not surprising in light of recent clinical studies on a related 
NF1-associated benign tumor, the plexiform neurofibroma, 
in which rapamycin analogs exhibited little clinical efficacy 
[32, 33]. Importantly, while carboplatin treatment clearly 
inhibited tumor growth in vivo, there was also little effect 
on the 25-core gene expression signature. This finding 
suggests that this time-tested chemotherapy may not 
normalize the tumor ecosystem. In this regard, tumor 
shrinkage is observed in the minority of children with 
NF1-OPG [34, 35], and, when observed, is often relatively 
modest or not longstanding (durable response) [36–38]. 
While neither anti-neoplastic cell therapy 
normalized the optic glioma core signature, minocycline 
treatment resulted in downregulation of this 25-core gene 
signature in the majority of mice (Figure 2C). Furthermore, 
analysis of the entire set of genes that were normalized 
by minocycline treatment using our deconvolution model 
showed that these alterations were largely associated 
with OPC-like cells, rather than microglia (Figure 2D). 
These results imply that blocking microglia function 
with minocycline has its greatest impact on the tumors 
themselves. This finding is consistent with recent RNA-
sequencing studies on Nf1 optic glioma-associated 
microglia, in which one chemokine (CCL5) made by 
these microglia positively regulates both microglia 
recruitment and glioma growth [19]. Future studies 
aimed at normalizing the tumor microenvironment using 
stroma-targeted treatments may prove most effective at re-
establishing a normal tissue ecosystem, and result in more 
durable glioma responses in human clinical trials.
A PTEN/PI3K-dependent gene signature is 
associated with poor glioma prognosis 
As noted above, Pten deletion altered both the 
lineage resemblance and core signature expression of 
the FMC optic glioma model. Heat map representation 
Figure 2: (A) Heatmap of RNA-Seq expression z-scores computed for the 25-gene core signature that is commonly differentially 
upregulated across all optic glioma models. (B) FMC mice treated with carboplatin at 3 months of age, and analyzed 1 month later, reveals 
decreased tumor volumes and percentages of Ki67+ cells. Control mice were treated with vehicle only and processed identically. *p < 0.05. 
Scale bar, 100 μm. (C) Same as (A), but for minocycline-treated and untreated FMC gliomas and FF controls. (D) Deconvolution of genes 
that are normalized in FMC by minocycline (highly or lowly expressed in FMC gliomas vs. FF controls, but either decreased or increased, 
respectively, by minocycline treatment).
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(Figure 3A) and deconvolution profiles (Figure 3B) 
revealed a differentially-expressed gene signature between 
FMC and FMPC specimens (Table 2). In the latter analysis, 
genes associated with the FMC and FMPC models were 
enriched in OPC-like and astrocytic gene expression, 
respectively. Importantly, these differentially-expressed 
signatures were not reflected in the relative abundance of 
either OPCs or astrocytes (Supplementary Figure 1). 
Because PTEN is a negative regulator of PI3K/
AKT signaling and Nf1 optic glioma growth [25] we 
hypothesized that pharmacologic inhibition of PI3K might 
normalize this differentially-expressed gene signature in 
FMPC mice. The ability of a PI3K-specific inhibitor, 
BKM120, to restore the FMC gene expression pattern 
in FMPC mice was revealed by sample-specific and 
average expression profiles (Figure 4A, 4B). Consistent 
with differential expression of OPC-associated genes in 
FMC tumors, deconvolution demonstrated a pronounced 
enrichment of OPC-associated genes in FMPC tumors 
following treatment with BKM120 (Figure 4C). These 
results demonstrate that a PI3K-regulated gene signature 
(Table 3) partly accounts for the differences observed 
between FMC and FMPC optic gliomas.
Since the heterozygous Pten deletion was restricted to 
the neoplastic cells by virtue of the fact that Cre-mediated 
Pten reduction was targeted to GFAP transgene-expressing 
cells containing somatic Nf1 loss, we sought to determine 
whether this signature was maintained in optic glioma 
stem cells (o-GSCs) that derived from FMC and FMPC 
mouse tumors. Previously, we showed that o-GSCs from 
FMC mice are true cancer stem cells, with the ability 
to self-renew, undergo multi-lineage differentiation, 
(Supplementary Figure 2) and form glioma-like lesions 
when transplanted into naïve mice [39]. RNA-seq was 
performed using independent isolates of o-GSCs from at 
least three pools of FMC and FMPC mice (n = 2 mice/
pool). Similar to that observed in the whole tumors, there 
was a relative depletion of the BKM120 normalized 
signature in FMC versus FMPC o-GSCs (Figure 4D), 
supporting a primary effect of heterozygous Pten deletion 
on the neoplastic cells in these gliomas. In addition, to 
determine whether BKM120 treatment normalizes this gene 
signature in purified o-GSCs, we treated separate pools of 
o-GSCs derived from FMPC mice with BKM120 in vitro 
and observed decreased PI3K/AKT activity (Supplementary 
Figure 3). As observed following BKM120 treatment of 
FMPC mice, we found the same signature to be significantly 
depleted in BKM120 treated o-GSCs relative to vehicle-
treated controls (Figure 4E). Taken together, the BKM120-
normalized gene signature behaves similarly in purified 
glioma stem cells and glioma tissue from the same models.
One of the clinically-relevant uses of these 
differentially-expressed gene signatures is their application 
to predicting survival in patients with gliomas.  We 
first examined the 25-gene core signature, common to 
all murine Nf1 optic gliomas, and found that it did not 
separate patients with either low-grade or high-grade 
gliomas into clinically-relevant subgroups based on overall 
survival or progression-free survival (data not shown). 
However, in striking contrast, differences in patient 
survival were observed using an expression signature 
comprised of the top 50 FMPC-associated genes that were 
most significantly normalized by BKM120 treatment 
(BKM120 normalized signature). For these analyses, gene 
set enrichment analysis (GSEA) was employed to assess 
the relative expression of this gene signature across human 
Figure 3: (A) Heatmap of RNA-Seq expression z-scores computed for genes that are differentially expressed (padj < 0.01, |log2(fold-
change)| > 1) between FMPC and FMC gliomas. (B) Deconvolution of genes that are differentially expressed between FMPC and FMC 
gliomas. In the top panel, each row in the heatmap corresponds to a specific differentially expressed gene and in each column corresponds 
to a cell type. The lower panel shows the aggregate expression in each cell type for all genes that are high in FMPC or FMC. The analysis 
shows that the FMC tumors are highly enriched in OPC-like gene expression compared to FMPC tumors, which are highly enriched in 
astrocytic gene expression. 
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Table 2: Genes differentially-expressed between FMC and FMPC optic gliomas
Genes with high expression in FMPC Name
A4galt alpha 1,4-galactosyltransferase
Actb actin, beta
Akap12 A kinase anchor protein 12
Alyref Aly/REF export factor
Angptl2 angiopoietin-like 2
Anxa11 annexin A11
Cd248 CD248 antigen, endosialin
Chrd chordin
Col3a1 collagen, type III, alpha 1
Ctgf connective tissue growth factor
Cxcl16 chemokine C-X-C motif ligand 16
D630003M21Rik unknown
Dbn1 drebrin 1
Dnaja4 DnaJ heat shock protein family member A4
Dpysl3 dihydropyrimidinase-like 3
Dusp1 dual specificity phosphatase 1
Ehd2 EH-domain containing 2
Gpr81 hydrocarboxylic acid receptor 1
Heyl hairy/enhancer-of-split related with YRPW motif-like
Hspb1 heat shock protein 1
Htra3 HtrA serine peptidase 3
Kdelr3 Lys-Asp-Glu-Leu endoplasmic reticulum protein retention receptor 3
Krt19 keratin 19
Lama4 laminin, alpha 4
Lgals3 galectin 3
Lmna lamin A
Loxl1 lysyl oxidase-like 1
Ltbp4 latent transforming growth factor beta binding protein 4
Mmp23 matrix metallopeptidase 23
Msc musculin
Mvp major vault protein
Mxra7 matrix-remodeling associated 7
Nbl1 neuroblastoma, suppression of tumorigenicity 1
Ntn1 netrin 1
Pam peptidylglycine alpha-amidating monooxygenase
Pamr1 peptidase domain containing associated with muscle regeneration 1
Ptrf polymerase I and transcript release factor
Rab3d RAB3D, member RAS oncogene family
Rasgef1b RasGEF domain family, member 1B
Rcn3 reticulocalbin 3, EF-hand calcium binding domain
Rnase1 ribonuclease, RNase A family, 1 
Sema3b sema domain, immunoglobulin domain, short basic domain, secreted, 3B
Serpinh1 serine (or cysteine) peptidase inhibitor, clade H, member 1
Spon2 spondin 2
Stk32c serine/threonine kinase 32C
Tgfbi transforming growth factor, beta induced
Tgm2 transglutaminase 2, C polypeptide
Tmem204 transmembrane protein 204
Tubb6 tubulin, beta 6 class V
1500009L16Rik unknown
Genes with low expression in FMPC Name
Abat 4-aminobutyrate aminotransferase
Abcd2 ATP-binding cassette, sub-family D (ALD), member 2
Acsbg1 acyl-CoA synthetase bubblegum family member 1
Agl amylo-1,6-glucosidase, 4-alpha-glucanotransferase
Apba2 amyloid beta precursor protein-binding, family A, member 2
Aqp4 aquaporin 4
Btbd17 BTB (POZ) domain containing 17
Cadm1 cell adhesion molecule 1
Chpt1 choline phosphotransferase 1
Cmip c-Maf inducing protein
Cntn1 contactin 1
Dmp1 dentin matrix protein 1
Elavl3 embryonic lethal, abnormal vision-like 3 
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low- and high-grade glioma surgical specimens collected 
and profiled by The Cancer Genome Atlas (TCGA) 
consortium (obtained from the Broad Institute GDAC 
Firehose site). In both low-grade (Figure 5A) and high-
grade (Figure 5B) glioma, patients with tumors depleted 
in the BKM120 treatment signature exhibited significantly 
enhanced progression-free survival relative to those with a 
PTEN-enriched signature.
Taken together, these data support a model in 
which murine Nf1 optic gliomas operate as an ecosystem 
composed of a diverse collection of cellular and acellular 
elements. The observation that the discovered 25-core 
differential gene expression pattern , which distinguishes 
tumor from non-neoplastic tissue, does not emanate 
from a single cell type (o-GSCs or microglia) argues 
that it represents networks of genes that are differentially 
expressed as a result of forming a tumor. This new ground 
state thus defines glioma at a molecular level, independent 
of gross morphological changes or alterations in cell 
composition or proliferation. Moreover, the established 
glioma gene expression profile provides a platform to 
evaluate potential chemotherapeutic agents, either alone 
or in combination, for their potential to normalize the 
tumor ecosystem and achieve greater treatment responses. 
In addition, co-existing genetic mutations targeted to the 
neoplastic cell compartment (Pten and Nf1 inactivation) can 
create differential core signatures that reflect the individual 
contributions of these molecular events to the cancer 
cells, which can be used to identify prognostic signatures 
relevant to patient survival and the potential interpretation 
of successful inhibition of the regulated growth control 
pathways. Future studies employing these types of 
approaches may be instructive, not only for defining 
what constitutes tumor, but also for identifying a possible 
Achilles heel network node for therapeutic targeting.
MATERIALS AND METHODS
Mice
FF (Nf1flox/flox), FMC (Nf1flox/mut; GFAP-Cre) FMPC 
(Nf1flox/mut; Ptenflox/wt; GFAP-Cre), F18C (Nf1 gene 
mutation c.2041C>T; p.R681X; Nf1flox/R681*; GFAP-Cre) 
mice were generated as previously described [23–25]. 
FMOC mice were generated by intercrossing Nf1flox/
mut mice with Olig2-Cre mice (B6-Olig2tm2 (TVA, cre)Rth/J; 
Jackson Laboratory; Nf1flox/mut; Olig2-Cre). All mice were 
maintained on a C57Bl/6 background and procedures 
performed in accordance with an approved Animal Studies 
Committee protocol at Washington University.
Elovl2 elongation of very long chain fatty acids-like 2
Elovl6 ELOVL family member 6, elongation of long chain fatty acids
Frrs1l ferric-chelate reductase 1 like
Fut9 fucosyltransferase 9
Gabrb1 gamma-aminobutyric acid A receptor, subunit beta 1
Gnaq guanine nucleotide binding protein, alpha q polypeptide
Gria2 glutamate receptor, ionotropic, AMPA2 
Gria4 glutamate receptor, ionotropic, AMPA4
Grin3a glutamate receptor ionotropic, NMDA3A
Gyk glycerol kinase
Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1
Itgb8 integrin beta 8
Kcna2 potassium voltage-gated channel, shaker-related subfamily, member 2
Kcnk1 potassium channel, subfamily K, member 1
Luzp2 leucine zipper protein 2
Mdga2 MAM domain containing glycosylphosphatidylinositol anchor 2
Ncan neurocan
Negr1 neuronal growth regulator 1
Nfia nuclear factor I/A
Nfib nuclear factor I/B
Nlgn1 neuroligin 1
Nrxn1 neurexin I
Paqr8 progestin and adipoQ receptor family member VIII
Pcdh15 protocadherin 15
Phka1 phosphorylase kinase alpha 1
Prex2 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2
Ptprd protein tyrosine phosphatase, receptor type, D
Ptprz1 protein tyrosine phosphatase, receptor type Z, polypeptide 1
Rgs7bp regulator of G-protein signalling 7 binding protein
Slc1a2 solute carrier family 1, member 2
Slc4a4 solute carrier family 4, member 4
Spag5 sperm associated antigen 5
Timp4 tissue inhibitor of metalloproteinase 4
Tmed5 transmembrane p24 trafficking protein 5
Tmem132b transmembrane protein 132B
Tmtc2 transmembrane and tetratricopeptide repeat containing 2
Tshz1 teashirt zinc finger family member 1
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Pharmacological studies 
50 mg/kg/day minocycline (Sigma-Aldrich; PBS, 
vehicle) was delivered by intraperitoneal (i.p.) injection 
5 days/week for two weeks [17]. 5 mg/kg/day rapamycin 
(Selleckchem; 5.2% Tween 80/5.2% polyethylene glycol 
400 as vehicle) was administered by i.p. injection 5 days/
week for two weeks [29]. 20 mg/kg/day NVP-BKM120 
(Selleckchem; N-methyl-2-pyrrolidone/ polyethylene 
glycol 300 (10/90v/v) as vehicle) was delivered by 
oral gavage 5 days/week for two weeks [40]. 60 mg/
kg/day carboplatin (Sigma-Aldrich; PBS as vehicle) 
was administered by i.p. injection every other day for 
1 week. All optic nerves were harvested two weeks 
after the initial injection, and processed for RNAseq, 
immunohistochemistry and optic nerve measurements as 
described below.
Optic nerve measurements 
Following perfusion with Ringers solution and 4% 
paraformaldehyde (PFA), optic nerves were photographed 
and volumes measured as previously described [29]. 
Immunohistochemistry
Optic nerves were microdissected and processed as 
described previously [41]. Antibodies used are listed in 
Supplementary Table 1. 
Cell culture
Optic glioma stem cells (o-GSCs) were isolated 
and maintained as previously described [39]. For NVP-
BKM120 treatments, cells were cultured in neural stem 
Figure 4:  (A) Heatmap of RNA-Seq expression z-scores computed for genes that are differentially expressed (padj < 0.01, |log2(fold-
change)| > 1) between FMPC and FMC gliomas across FMC, FMPC, and BKM120-treated FMPC gliomas. Many of the differentially 
expressed genes are normalized by BKM120 treatment. (B) Same as (A), but averaged over all samples for each group. (C) Deconvolution 
of genes that are differentially expressed between BKM120-treated and untreated FMPC gliomas. In the top panel, each row in the heatmap 
corresponds to a specific differentially-expressed gene and in each column corresponds to a cell type. The lower panel shows the aggregate 
expression in each cell type for all genes that are high in BKM120-treated and untreated FMPC tumors. The analysis shows that the treated 
tumors are highly enriched in OPC-like gene expression (similar to the FMC tumors) compared to the untreated tumors. (C) GSEA showing 
enrichment of the 50-gene BKM120 normalization signature in the RNA-Seq profile of FMPC- compared to FMC-derived o-GSCs. (D) 
GSEA showing depletion of the 50-gene BKM120 normalization signature in BKM120-treated FMPC-derived o-GSCs compared to 
vehicle-treated cells.
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Table 3: Genes comprising the 50-core signature responsive to BKM-120 inhibition
Gene Name
Actb actin, beta
Akr1a1 aldo-keto reductase family 1 member A1
Aldoa aldolase, fructose-biphosphate A
Alyref Aly/REF export factor
Arf5 ADP ribosylation factor 5
Arl4d ADP ribosylation factor-like GTPase 4D
Arpc3 actin-related protein 2/3 complex subunit 3
Atp6v1f ATPase H+ transporting V1 subunit F
Cct5 chaperonin-containing TCP1 subunit 5
Cd81 CD81 antigen
Cdc37 cell division cycle 37
Cdr1 cerebellar degeneration related protein 1
Cebpb CCAAT/enhancer binding protein, beta
Chp2 calcineurin-like EF-hand protein 2
Cilp cartilage intermediate layer protein
Dpysl2 dihydropyrimidinase like 2
Dusp1 dual specificity phosphatase 1
Dynll1 dynein light chain LC8-type 1
Eif3d eukaryotic translation initiation factor 3 subunit D
Ftl1 ferritin light polypeptide 1
Fxyd1 FXYD domain-containing ion transport regulator 1
Gpr81 hydroxycarboxylic acid receptor 1
Herpud1 homocysteine inducible ER protein with ubiquitin-like domain 1
Hnrnpl heterogeneous nuclear ribonucleoprotein
Ifitm2 interferon-induced transmembrane protein 2
Irf2bp2 interferon regulatory factor 2 binding protein 2
Kdelr3 KDEL endoplasmic reticulum protein retention receptor 3
Loxl1 lysyl oxidase like 1
Lsp1 lymphocyte-specific protein 1
Map1lc3b microtubule-associated protein 1 light chain 3 beta
Mrpl12 mitochondrial ribosomal protein L12
Oat ornithine aminotransferase
Opalin oligodendrocytic myelin paranodal and inner loop protein
Pam peptidylglycine alpha-amidating monooxygenase
Plat plasminogen activator, tissue type
Plekhf1 pleckstrin homology and FYVE domain containing 1
Rasgef1b RasGEF domain family member 1B
Rhoc ras homolog family member C
Slc6a13 solute carrier family 6 member 13
Snrpb small ribonuclear ribonucleoprotein polypeptides B and B1
Spon2 spondin 2
Sqstm1 sequestosome 1
Tgfbi transforming growth factor, beta-induced
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cell medium without EGF and bFGF for 1 hour, followed 
by treatment with DMSO (vehicle) or 0.2 µM NVP-
BKM120 for 5 hours at 37°C, and cells harvested for RNA 
isolation or western blotting. 
Western blotting
Cells were lysed as described previously and 
western blotting performed using the antibodies listed in 
Supplementary Table 1 [42, 43].
Immunocytochemistry
o-GSCs were adhered to fibronectin (50 μg/ml)/
poly-D-lysine (10 μg/ml)-coated surfaces and cultured 
in neural stem cell medium supplemented with N2, 
B27, EGF and bFGF for 24 hours at 37°C and fixed 
with 4% PFA for immunostaining. o-GSCs were also 
differentiated as previously described [39], fixed with 
4% PFA, and immunostained with the antibodies listed in 
Supplementary Table 1. 
RNA extraction and mRNA isolation
RNA was extracted from Trizol-preserved 
tissue and cell lysates using isopropanol precipitation. 
Each total RNA sample was re-suspended in 20 uL 
of nuclease-free water supplemented with 0.5 U/uL 
RNase inhibitor (SUPERaseIN, Life Technologies). 
A 5′-biotinylated, LNA-enhanced oligo(dT) capture 
probe (Exiqon) was used to isolate poly(A)+ mRNA as 
described previously [44].
Tppp3 tubulin polymerization promoting protein family member 3
Tram1 translocation-associated membrane protein 1
Ubb ubiquitin B
Vtn vitronectin
Wdr1 WD repeat domain 1
Ywhaz tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
1810011O10Rik unknown
Figure 5:  Progression-free survival curves for human low-grade gliomas (A) and glioblastomas (B) that are either highly enriched or 
depleted of the top 50 genes that are differentially expressed between FMPC and FMC gliomas and most significantly normalized by 
BKM120 treatment of FMPC gliomas. Depletion of the 50-gene BKM120 normalization signature is associated with better progression-
free survival in both low-grade (p = 0.015) and high-grade (p = 0.034) human brain tumors.
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Library construction and sequencing
RNA-Seq libraries were constructed using 
SMARTer Stranded RNA-Seq kit (Clontech Laboratories) 
according to the manufacturer’s instructions. mRNA was 
fragmented for 4 minutes at 94°C and cDNA libraries were 
purified twice using AMPure XP beads (Beckman) prior 
to PCR enrichment. After PCR enrichment, the resulting 
sequencing libraries were quantified using a Bioanalyzer 
(Agilent) and Qubit (ThermoFisher). The libraries were 
pooled and sequenced on an Illumina NextSeq 500 using 
75-cycle High Output Kits.
RNA-Seq data processing
Prior to sequence alignment, the first five nucleotides 
from the 5′-end of each read were clipped to eliminate the 
GC-rich, template-switching sequence inserted during 
reverse transcription. The reads were aligned to the mouse 
genome and transcriptome (mm10, USCS annotation from 
Illumina iGenomes) using Tophat 2 [45]. HTSeq was used 
to quantify the number of reads associated with each gene 
and DESeq2 for differential expression analysis [46]. The 
RNA-seq data will be deposited in GEO.
Deconvolution of cell type-specific gene 
expression and gene set enrichment analysis
Computational deconvolution of cell type-specific 
gene expression was accomplished using the methods 
described in our previous studies [27, 28] with one 
improvement. As cell type-specific markers, we used 
Cspg4 (OPC), Gfap (astrocyte), Mog (oligodendrocyte), 
Rbfox3 (neuron), and Aif1 (microglia). Gene set 
enrichment analysis was conducted using the GSEA 
software package available from the Broad Institute. 
For all of the GSEA presented here, we used pre-ranked/
classical mode to compute enrichment scores.
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